Room: Truhlsen Events Center, Room 1001 A

• Chair: Sam Hanash, MD, MD Anderson Cancer Center
• Co-chair: David Sidransky, MD, Johns Hopkins University
• Andrew Hoofnagle, MD, PhD, University of Washington
• Gerard Davis, PhD, Abbott Laboratories
• Mark Driscoll, PhD, Intus Biosciences
• DMCC Statistician: Ziding Feng, PhD, Fred Hutchinson Cancer Center
• DMCC Staff: Kristin Rodgers, Fred Hutchinson Cancer Center
• NCI PD: Sudhir Srivastava, PhD, MPH, National Cancer Institute

Agenda

Suggested Discussion Points:

• Real-world examples of successful partnerships and their impact on early cancer detection technologies.
• Industrial partnerships' role in translating academic findings into practical diagnostic tools.
• Key challenges in moving from research to real-world application, including regulatory hurdles.
• Strategies for fostering collaboration between academic researchers and industrial partners.
• Overcoming challenges related to reproducibility, scalability, and regulatory approval.
• Best practices for technology transfer and IP agreements that benefit both academic institutions and industrial partners.
• The role of collaborative platforms, consortia, and networks in advancing early detection and biomarker validation.
• Strategies for effective collaboration between academic institutions and industry in designing and conducting biomarker-driven clinical trials.
• Potential funding opportunities to support academic-industrial collaborations.
• Identifying future areas of collaboration between academia and industry in early cancer detection and biomarker validation.